Fischer Medical Ventures Share Price
22.33+0.01 (-2.32%)
-45.50% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
ADANIENTNSE
CPPLUSNSE
AEGISLOGNSE
PREMIERENENSE
REDINGTONNSE
HONASANSE
SGMARTNSE
LLOYDSENTNSE
ENTERONSE
CELLONSE
FISCHERNSE
Fischer Medical Ventures Share Price
22.33+0.01 (-2.32%)
-45.50% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 1098% | 179% |
| - | - | - | 1743% |
| - | - | - | -45% |
| 4% | 4% | 5% | 9% |
Peer Comparison
Symbol
ADANIENT
CPPLUS
AEGISLOG
PREMIERENE
REDINGTON
HONASA
SGMART
LLOYDSENT
ENTERO
CELLO
FISCHER
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 2,689.5 | ₹365234 Cr | 63.65 | 11.02 | 97.19 | ₹9339 Cr |
| 4,045.7 | ₹49371 Cr | 83.28 | 15.13 | 53.43 | ₹368 Cr |
| 1,155.5 | ₹44400 Cr | 33.33 | 7.42 | 40.69 | ₹898 Cr |
| 826.25 | ₹37723 Cr | 21.32 | 10.09 | 46.95 | ₹1510 Cr |
| 336 | ₹26682 Cr | 14.39 | 6.92 | 26.4 | ₹1490 Cr |
| 528.3 | ₹17272 Cr | 61.09 | 2.24 | 9.99 | ₹200 Cr |
| 1,023.5 | ₹12721 Cr | 83.79 | 4.28 | 13.3 | ₹111 Cr |
| 63.07 | ₹9779 Cr | 95.38 | 0.09 | 0.89 | ₹283 Cr |
| 1,966.3 | ₹8614 Cr | 61.82 | 10.46 | 43.47 | ₹115 Cr |
| 359.9 | ₹8198 Cr | 26.53 | 3.63 | 17.5 | ₹332 Cr |
| 22.36 | ₹1598 Cr | 95.5 | 0.01 | 0.3 | ₹30 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹107 Cr | ₹82 Cr | ₹98 Cr | ₹101 Cr | ₹86 Cr | ₹23 Cr | ₹49 Cr | ₹12 Cr | ₹40 Cr | ₹10 Cr | ₹21 Cr |
| ₹5 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹7 Cr | ₹15 L | ₹38 L | ₹22 L | ₹74 L | ₹47 L |
| ₹112 Cr | ₹83 Cr | ₹99 Cr | ₹102 Cr | ₹89 Cr | ₹31 Cr | ₹49 Cr | ₹12 Cr | ₹40 Cr | ₹11 Cr | ₹21 Cr |
| ₹100 Cr | ₹72 Cr | ₹98 Cr | ₹80 Cr | ₹71 Cr | ₹20 Cr | ₹47 Cr | ₹12 Cr | ₹39 Cr | ₹11 Cr | ₹18 Cr |
| ₹14 Cr | ₹13 Cr | ₹2 Cr | ₹23 Cr | ₹19 Cr | ₹12 Cr | ₹3 Cr | ₹88 L | ₹72 L | ₹48 L | ₹3 Cr |
| ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹64 L | ₹92 L | ₹66 L | ₹23 L | ₹7 L | ₹5 L | ₹13 L | ₹5 L |
| ₹9 Cr | ₹8 Cr | -₹2 Cr | ₹21 Cr | ₹17 Cr | ₹10 Cr | ₹2 Cr | ₹25 L | ₹38 L | ₹8 L | ₹3 Cr |
| ₹81 L | ₹4 Cr | -₹7 Cr | ₹19 Cr | ₹14 Cr | ₹5 Cr | ₹1 Cr | -₹17 L | ₹46 L | -₹12 L | ₹3 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹65 Cr | ₹64 Cr | ₹54 Cr | ₹17 L |
| ₹26 Cr | ₹30 Cr | ₹87 L | ₹0 |
| ₹293 Cr | ₹243 Cr | ₹27 Cr | -₹44 L |
| ₹293 Cr | ₹243 Cr | ₹27 Cr | -₹44 L |
| ₹384 Cr | ₹338 Cr | ₹81 Cr | -₹27 L |
| ₹76 L | ₹34 L | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹57 L |
| ₹26 L | ₹26 L | ₹0 | ₹0 |
| -₹2 Cr | ₹53,000 | ₹12 L | -₹11 L |
| ₹27 Cr | ₹17 Cr | ₹1 Cr | ₹0 |
| ₹99 L | ₹9 L | ₹0 | ₹0 |
| ₹26 Cr | ₹17 Cr | ₹1 Cr | ₹47 L |
| — | — | — | — |
| ₹103 Cr | ₹21 Cr | ₹2 Cr | ₹1 L |
| ₹23 Cr | ₹23 Cr | ₹2 Cr | ₹3 L |
| ₹72 Cr | ₹60 Cr | ₹0 | ₹0 |
| ₹61 Cr | ₹1 Cr | ₹90,000 | ₹0 |
| ₹258 Cr | ₹105 Cr | ₹4 Cr | ₹5 L |
| ₹669 Cr | ₹461 Cr | ₹86 Cr | ₹25 L |
| ₹72 Cr | ₹60 Cr | ₹0 | ₹57 L |
| — | — | — | — |
| ₹38 Cr | ₹27 Cr | ₹16 Cr | ₹0 |
| ₹6 Cr | ₹3 Cr | ₹1 Cr | ₹0 |
| ₹32 Cr | ₹24 Cr | ₹15 Cr | ₹0 |
| ₹3 Cr | ₹1 Cr | ₹0 | ₹0 |
| ₹118 Cr | ₹7 Cr | ₹1 Cr | ₹0 |
| ₹118 Cr | ₹7 Cr | ₹1 Cr | ₹0 |
| ₹50 Cr | ₹22 Cr | ₹0 | ₹0 |
| ₹49 Cr | ₹38 Cr | ₹0 | ₹0 |
| ₹251 Cr | ₹92 Cr | ₹16 Cr | ₹0 |
| — | — | — | — |
| ₹13 Cr | ₹9 Cr | ₹4 Cr | ₹0 |
| ₹289 Cr | ₹76 Cr | ₹23 Cr | ₹17 L |
| ₹25 Cr | ₹255 Cr | ₹38 Cr | ₹4 L |
| ₹6 Cr | ₹3 Cr | ₹45 L | ₹0 |
| ₹86 Cr | ₹26 Cr | ₹5 Cr | ₹4 L |
| ₹418 Cr | ₹369 Cr | ₹70 Cr | ₹25 L |
| ₹160 Cr | ₹263 Cr | ₹67 Cr | ₹20 L |
| ₹669 Cr | ₹461 Cr | ₹86 Cr | ₹25 L |
| ₹5 | ₹48 | ₹15 | -₹15 |
| ₹5 | ₹5 | ₹1 | -₹2 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹45 Cr | ₹2 Cr | ₹2 Cr | ₹0 |
| ₹15 Cr | ₹3 Cr | ₹25 L | ₹0 |
| -₹144 Cr | -₹90 Cr | -₹10 Cr | ₹0 |
| -₹84 Cr | -₹85 Cr | -₹7 Cr | ₹0 |
| -₹101 Cr | -₹86 Cr | -₹7 Cr | ₹0 |
| -₹5 Cr | -₹125 Cr | -₹31 Cr | ₹0 |
| ₹14 Cr | ₹315 Cr | ₹37 Cr | ₹0 |
| -₹92 Cr | ₹103 Cr | -₹2 Cr | ₹0 |
| ₹104 Cr | ₹95 L | ₹4 L | ₹0 |
| ₹0 | ₹0 | ₹3 Cr | ₹0 |
| ₹0 | ₹50,000 | ₹0 | ₹0 |
| ₹12 Cr | ₹104 Cr | ₹95 L | ₹0 |
Fundamental Ratios
Consolidated
Standalone

No results found
Fischer Medical Ventures Share Price
22.33+0.01 (-2.32%)
-45.50% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 6 out of 9 oscillators
RSI
27.19Sell
STOCH %K
1.70Buy
MACD Level(12,26)
-1.65Sell
Ultimate Oscillator
27.71Sell
Aroon Oscillator
-60.00Sell
BOP
-0.56Sell
CCI
-202.19Buy
Williams %R
-98.30Buy
Momentum
-2.33Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 9 out of 9 moving averages
EMA 9
23.68Sell
SMA 9
24.00Sell
EMA 21
25.07Sell
SMA 21
24.74Sell
EMA 50
28.24Sell
SMA 50
29.00Sell
EMA 200
41.03Sell
SMA 200
35.53Sell
WMA 20
24.20Sell
Pivot
Pivot
Classic
Resistance 5
25.59
Resistance 4
24.92
Resistance 3
24.25
Resistance 2
23.58
Resistance 1
23.22
Pivot
22.91
Support 1
22.55
Support 2
22.24
Support 3
21.57
Support 4
20.90
Support 5
20.23
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Fischer Medical Ventures Share Price
22.33+0.01 (-2.32%)
-45.50% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 63.08% | 62.15% | 62.15% | 61.80% | 61.80% | 61.80% |
| 6.71% | 5.48% | 4.97% | 4.85% | 5.57% | 5.55% |
| 1.26% | 1.35% | 1.38% | 1.36% | 1.42% | 1.42% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 28.95% | 31.02% | 31.50% | 31.99% | 31.21% | 31.23% |
Bulk & block deals
Name
Trade Solvent Private Limited
L7 Hitech Private Limited
L7 Hitech Private Limited
Anand Mohan
Ravindradadajijilte
Mohammadzahidhussain
Arunkumar
Omkar Ashok Shinde
Suresh Sabanna Itkal
Kantilal B Shah
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 22 Sep 2026 | Purchase | 21.21 Cr | ₹32.95 | 64.37 L | Bulk | 0.929268 | NSE |
| 22 Sep 2026 | Purchase | 1.01 Cr | ₹32.98 | 3.05 L | Bulk | 0.044032 | NSE |
| 22 Sep 2026 | Sell | 21.21 Cr | ₹32.95 | 64.37 L | Bulk | 0.929268 | NSE |
| 10 Apr 2023 | Sell | 1 L | ₹79.80 | 1.26 K | Bulk | 0.000182 | BSE |
| 27 Dec 2021 | Sell | 90.75 K | ₹93.27 | 973 | Bulk | 0.00014 | BSE |
| 27 Dec 2021 | Purchase | 93.20 K | ₹93.20 | 1 K | Bulk | 0.000144 | BSE |
| 23 Aug 2021 | Purchase | 83.95 K | ₹90.07 | 932 | Bulk | 0.000135 | BSE |
| 09 Mar 2018 | Sell | 12.56 K | ₹12.56 | 1 K | Bulk | 0.000144 | BSE |
| 09 Mar 2018 | Purchase | 11.25 K | ₹12.50 | 900 | Bulk | 0.00013 | BSE |
| 09 Jan 2015 | Purchase | 77.18 K | ₹2.68 | 28.80 K | Bulk | 0.004158 | BSE |
Insider trading & SAST
Client name
Shankar Varadharajan & Others
Shankar Varadharajan & Pacs
Shankar Varadharajan & Pacs
Shankar Varadharajan & Pacs
Shankar Varadharajan & Others
Fmv Holdings Pte Ltd
Fmv Holdings Pte Ltd
Shankar Varadharajan
Fmv Holdings Pte Ltd
Shankar Varadharajan
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27 Aug 2026 | Promoter | Acquisition | 1.66 | 63 | 0 | — | 1.13 Cr | 13 Aug 2026 | Pref. Allotment | 42,69,72,531 | SAST | 29(2) | — |
| 27 Aug 2026 | Promoter | Acquisition | 0.35 | 62.5 | 0 | — | 23 L | 11 Aug 2026 | Pref. Allotment | 40,90,62,650 | SAST | 29(2) | — |
| 27 Aug 2026 | Promoter | Acquisition | 1.91 | 63.06 | 0 | — | 1.33 Cr | 14 Aug 2026 | Pref. Allotment | 44,03,08,440 | SAST | 29(2) | — |
| 27 Aug 2026 | Promoter | Acquisition | 1 | 62.66 | 0 | — | 66.32 L | 12 Aug 2026 | Pref. Allotment | 41,56,94,314 | SAST | 29(2) | — |
| 27 Aug 2026 | Promoter | Acquisition | 0.07 | 63.08 | 0 | — | 4.54 L | 17 Aug 2026 | Pref. Allotment | 44,07,62,650 | SAST | 29(2) | — |
| 18 Aug 2026 | Promoter | Acquisition | 0.065615 | 50.78 | 1.06 Cr | ₹23.40 | 4.54 L | 17 Aug 2026 | Conversion of security | 35,47,61,120 | Insider Trading | — | Equity |
| 17 Aug 2026 | Promoter | Acquisition | 1.092099 | 50.74 | 17.17 Cr | ₹23.40 | 73.36 L | 14 Aug 2026 | Conversion of security | 35,43,06,910 | Insider Trading | — | Equity |
| 17 Aug 2026 | Promoter | Acquisition | 0.893222 | 12.32 | 14.04 Cr | ₹23.40 | 60 L | 14 Aug 2026 | Conversion of security | 8,60,01,530 | Insider Trading | — | Equity |
| 17 Aug 2026 | Promoter | Acquisition | 1.059748 | 50.74 | 17.17 Cr | ₹23.40 | 73.36 L | 14 Aug 2026 | Conversion of security | 35,43,06,910 | Insider Trading | — | Equity |
| 17 Aug 2026 | Promoter | Acquisition | 0.866762 | 12.32 | 14.04 Cr | ₹23.40 | 60 L | 14 Aug 2026 | Conversion of security | 8,60,01,530 | Insider Trading | — | Equity |
Fischer Medical Ventures Share Price
22.33+0.01 (-2.32%)
-45.50% past 1 Year
Fischer Chemic Ltd is a certified supplier of APIs&intermediate Herbal Medicine Food Additives Cosmetics Raw Materials Laboratory Instrument&Chemicals PVC Modifier Aquaculture equipments etc. They have two manufacturing bases located in
Corporate Actions
Date
Type
Details
Company details
Fischer Medical Ventures Share Price
22.33+0.01 (-2.32%)
-45.50% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Fischer Medical Ventures Share Price
22.33+0.01 (-2.32%)
-45.50% past 1 Year
News
1 of 20
ResultFISCHER14 Nov 2026
NULL
Fischer Medical Ventures Approves Rs 50 Crore Investment In Subsidiary Rights Issues
Stock NewsFISCHER24 Sept 2026
Fischer Medical Ventures has approved an investment of Rs 50 crores in the rights issues of three subsidiaries. The company did not disclose the individual allocation among the subsidiaries, issue pricing, proposed shareholding changes, or the specific utilisation plans for the funds. The investment is expected to support the subsidiaries capital requirements and may strengthen the companys presence across its medical ventures businesses, subject to execution and future financial performance.
The announcement represents a routine corporate funding action and does not by itself establish an immediate change in consolidated earnings, leverage, or market share. Fischer Medical Ventures shares closed at Rs 34.61 on September 24, 2026, compared with Rs 35.03 on September 23, 2026.
Fischer Medical Ventures expands Southeast Asia imaging footprint via new deployment initiative
Stock NewsFISCHER7 Sept 2026
Fischer Medical Ventures Limited, listed on NSE and BSE under the symbol FISCHER, has announced a significant expansion of its healthcare and diagnostic imaging presence in Southeast Asia through a new development initiative focused on advanced imaging solutions. The company operates in the medical equipment and supplies space and has been positioning itself as an emerging player in high-end diagnostic and imaging technologies, including MRI systems and AI-enabled portable X-ray platforms. Recent strategic moves in markets such as Indonesia and broader ASEAN geographies underscore its intent to deepen its operational footprint across key Southeast Asian healthcare ecosystems.
While the context headline references a 3.00 lakh crores imaging development, there is no verifiable regulatory or mainstream financial disclosure supporting this specific quantum, and therefore no precise capex or contract value in Rs crores can be reliably stated. Available information indicates that Fischer Medical Ventures, through its subsidiaries and partnerships, is targeting expansions in telehealth, teleradiology, and AI-driven diagnostic imaging, with deployments designed to improve access to imaging in underserved regions, enhance public health screening programmes, and leverage cloud-based reporting and AI triage capabilities. Strategically, this Southeast Asia push is likely aimed at building recurring hardware and service revenues, strengthening market share in regional medtech, and creating operating leverage as installations scale.
For Indian investors, the development highlights Fischer Medical Ventures’ growing international exposure and its focus on technology-led healthcare solutions beyond the domestic market. The company’s involvement in large-scale deployments of portable imaging units and telehealth platforms suggests potential long-term benefits for topline growth and margin improvement, although near-term earnings impact and exact financial contribution from these Southeast Asian initiatives remain undisclosed. In the absence of verified data on deal values in Rs , stake changes, or specific regulatory filings tied to this exact announcement, the news is best interpreted as a strategic expansion update reinforcing the company’s regional growth ambitions in diagnostic imaging and digital health.
Fischer Medical Ventures to hold analyst and investor meet on September 7
Stock NewsFISCHER4 Sept 2026
Fischer Medical Ventures has announced plans to conduct a meeting with analysts and investors on September 7. The scheduled interaction indicates the company’s intent to engage more actively with the market community, providing an opportunity for management to share business updates, strategic priorities, and operational insights with institutional and retail stakeholders. Such meetings are typically used to clarify growth plans, address queries on financial performance, and outline medium-term outlook, thereby improving transparency and communication between the company and the investment fraternity.
While the specific agenda, format, and duration of the September 7 meeting are not disclosed in the available information, the initiative suggests that Fischer Medical Ventures is focusing on enhancing its investor relations framework. Regular engagement of this nature can help the company better articulate its positioning within the medical and healthcare-related segments, explain recent developments, and manage expectations around future performance. It may also allow analysts to refine their forecasts and valuation models based on direct management commentary, which can influence research coverage and institutional interest over time.
No additional details have been provided on concurrent corporate actions such as fund raising, mergers and acquisitions, stake changes, or regulatory orders linked to this announcement. There is also no verifiable information on immediate stock price movement or trading volumes in connection with the planned meeting. In the absence of explicit guidance on financial metrics or strategic transactions, the development appears primarily oriented toward improving communication rather than signaling a material change in earnings profile, leverage, or market share in the near term.
Fischer Medical Ventures subsidiary launches Clarion AI CT system in India
Stock NewsFISCHER28 Aug 2026
Fischer Medical Ventures, listed on NSE as FISCHER and BSE as 524743, has announced that its subsidiary has introduced the Clarion 64/128-slice AI-powered CT system in the Indian market. This move positions the company more firmly within advanced diagnostic imaging, complementing its existing focus on medical equipment including CT and MRI systems. The Clarion platform, with 64/128-slice configuration and embedded AI capabilities, is likely aimed at enhancing scan quality, workflow efficiency and diagnostic accuracy across high-throughput radiology centres, tertiary care hospitals and specialised diagnostic chains.
The introduction of an AI-powered CT solution can support Fischer Medical Ventures in strengthening its product bouquet within medical imaging, potentially improving its ability to compete against established multinational vendors in the CT segment. Depending on pricing and service strategy, this product may allow the company to target mid-sized and large hospitals looking to upgrade from legacy scanners to more advanced, higher-slice technology. Over time, successful commercialization of Clarion could contribute to higher revenue growth and margin improvement, given the relatively premium pricing and service annuity typically associated with advanced imaging systems and maintenance contracts.
From an earnings perspective, the impact will depend on order wins, installation pipeline, and the company’s ability to scale manufacturing, distribution and after-sales support for Clarion across key geographies in India. The launch itself does not alter leverage or capital structure, but it suggests continued strategic focus on high-end diagnostic equipment rather than pure commodity chemicals trading. While near-term stock price impact cannot be precisely quantified without intraday trading data, such product launches are generally viewed as positive for long-term positioning, especially if backed by hospital tie-ups, clinical validation and competitive pricing in comparison to global peers in the CT imaging space.
Fischer Medical Ventures gets CDSCO nod for Spincare wound care device
Stock NewsFISCHER30 Jul 2026
Fischer Medical Ventures has secured CDSCO import approval for Spincare, described as India's first portable electrospun wound care system. This regulatory clearance allows the company to import and market the advanced wound care device in India, positioning it in a niche segment within medical technology and hospital supplies. The product's portable electrospun technology is aimed at improving clinical outcomes in wound management, which could enhance Fischer Medical Ventures' value proposition to hospitals, clinics and advanced care centres. With this approval, the company can begin to build a presence in the high-potential wound care market where demand is supported by rising healthcare expenditure, growth in chronic disease-related wounds and an increasing focus on infection control and faster healing.
The company has also secured exclusive distribution rights for Spincare in India and Southeast Asia. This exclusivity gives Fischer Medical Ventures a clear commercial edge, as it can control pricing strategy, market development and channel partnerships across multiple geographies without direct competition on the same product. Over time, if execution is strong, this could support revenue scale-up, improve margins through better pricing power and strengthen its market share in advanced wound care solutions. Additionally, FDA approval for Spincare is stated to be in progress. If and when US FDA clearance is obtained, it would enhance the global credibility of the device and can be leveraged in marketing and clinician adoption across India and Southeast Asia. However, specific financial details including projected revenues, capex commitments, margin impact, or current stock price reaction are not disclosed in the available information, so earnings impact remains indicative rather than quantifiable at this stage.
Fischer Medical Ventures informs about outcome of board meeting
Stock NewsFISCHER30 May 2026
NULL
Fischer Medical reports Profit after tax of Rs -8.98 Crores, in the March 2026 quarter
ResultFISCHER29 May 2026
NULL
Fischer Medical Ventures informs about appointment of CS cum CO
Stock NewsFISCHER24 Mar 2026
NULL
Fischer Medical - Quaterly Results
ResultFISCHER30 Jan 2026
NULL
Fischer Medical Ventures Q3 FY26 EBITDA Surges to Rs 21.60 Crores, Margin Expands to 21.34% YoY.
ResultFISCHER30 Jan 2026
Fischer Medical Ventures Ltd reported strong Q3 FY26 results with EBITDA at Rs 21.60 crores, up significantly from Rs 50 lakhs YoY. EBITDA margin expanded to 21.34% from 4.26% YoY. Revenue reached Rs 88.79 crores in Sep '25 quarter, reflecting 187.25% QoQ growth from Rs 30.91 crores. EBITDA grew 60.98% QoQ to Rs 18.69 crores from Rs 11.61 crores. Net profit stood at Rs 13.9 crores, up 177.45% QoQ from Rs 5.01 crores.
Additional metrics include total revenue of Rs 86.31 crores and operating profit of Rs 3.40 crores. Results were announced on Jan 30, 2026, aligning with typical mid-January schedule for Q3. Stock price showed recent volatility, trading around Rs 34-39 in late January 2026.
Fischer Medical Ventures Reports Q3 Net Profit of Rs 19.20 Crores, Revenue Rs 100 Crores YoY.
ResultFISCHER30 Jan 2026
Fischer Medical Ventures announced strong Q3 results with consolidated net profit at Rs 19.20 crores, reversing a YoY loss of Rs 30.00 lakhs. Revenue surged to Rs 100.00 crores from Rs 11.70 crores in the previous year, reflecting robust YoY growth.
Key financial highlights include significant top-line expansion and profitability turnaround. Supporting data from recent quarters shows Q2 Sep '25 revenue at Rs 88.79 crores (up 187.25% QoQ from Rs 30.91 crores), EBITDA Rs 18.69 crores (up 60.98% QoQ), and net profit Rs 13.90 crores (up 177.45% QoQ). TTM revenue stands at Rs 1.71 billion with net profit Rs 199.36 million, gross margin 28.86%, and net profit margin 11.68%.
No specific EBITDA, margin trends, or street expectations mentioned in the update. Stock traded around Rs 34-37 in late January 2026.
Key financial highlights include significant top-line expansion and profitability turnaround. Supporting data from recent quarters shows Q2 Sep '25 revenue at Rs 88.79 crores (up 187.25% QoQ from Rs 30.91 crores), EBITDA Rs 18.69 crores (up 60.98% QoQ), and net profit Rs 13.90 crores (up 177.45% QoQ). TTM revenue stands at Rs 1.71 billion with net profit Rs 199.36 million, gross margin 28.86%, and net profit margin 11.68%.
No specific EBITDA, margin trends, or street expectations mentioned in the update. Stock traded around Rs 34-37 in late January 2026.
Fischer Medical Ventures Board Approves Restructuring of Malaysian Subsidiary Shareholding.
Stock NewsFISCHER30 Jan 2026
Fischer Medical Ventures Limited's Board has approved a restructuring of its shareholding in Malaysian subsidiary Fischer Hospitality Sdn. Bhd. (FHSB). Under the new structure, a Malaysian trustee will hold 51% of FHSB shares on behalf of the company, while Fischer Medical Ventures will directly hold the remaining 49%. This proposal has been reviewed and approved by the Audit Committee.
Fischer Hospitality Sdn. Bhd., incorporated in September 2024 and based in Melaka, operates as an investment holding entity focused on healthcare and medical technology sectors in Southeast Asia. The company previously held a 60% stake in FHSB, making it a subsidiary. This restructuring adjusts the direct shareholding pattern while maintaining the company's beneficial interest.
The move aligns with ongoing corporate developments, including strong Q3FY26 performance with consolidated revenue of Rs 10,109.52 lakhs and net profit of Rs 1,923.48 lakhs. No specific quantum of shares transferred or financial impact was detailed in the announcement. The restructuring may streamline ownership for regulatory or operational purposes in Malaysia.
Fischer Medical reports Profit after tax of Rs -1.67 Crores, in the December 2025 quarter
ResultFISCHER30 Jan 2026
NULL
Fischer Medical Ventures Restructures Pellucidcare Health Innovations Transfer to Subsidiary
Stock NewsFISCHER21 Jan 2026
Fischer Medical Ventures Limited's Executive Business Committee has approved the internal transfer of Pellucidcare Health Innovations to its wholly owned subsidiary as part of a corporate restructuring initiative. This strategic move represents an organizational realignment within the MedTech conglomerate, consolidating diagnostic and healthcare solutions under subsidiary operations.
Fischer Medical Ventures, headquartered in Chennai with manufacturing facilities in Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam, is India's first company to indigenously manufacture advanced MRI systems. The company operates across multiple business verticals including cost-efficient magnetic resonance imaging systems, diagnostic imaging solutions, and digital health innovations. Recent corporate actions demonstrate FMV's diversification strategy, including investments in voice-AI mental health diagnostics (Wonder Tech Group), hospitality healthcare hubs in Malaysia, and diagnostic solution partnerships.
The Pellucidcare restructuring aligns with FMV's broader expansion in point-of-care diagnostic solutions and reinforces its strategic positioning in the diagnostic healthcare ecosystem. This internal reorganization optimizes operational efficiency and consolidates diagnostic capabilities within the subsidiary structure, supporting the company's stated vision of leveraging AI, Big Data, and Computing (ABC framework) to enhance healthcare accessibility and affordability.
The transfer reflects FMV's commitment to vertical integration and portfolio optimization within India's growing diagnostic imaging sector, though the specific financial quantum and transaction timelines remain subject to regulatory approvals.
Fischer Medical Ventures, headquartered in Chennai with manufacturing facilities in Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam, is India's first company to indigenously manufacture advanced MRI systems. The company operates across multiple business verticals including cost-efficient magnetic resonance imaging systems, diagnostic imaging solutions, and digital health innovations. Recent corporate actions demonstrate FMV's diversification strategy, including investments in voice-AI mental health diagnostics (Wonder Tech Group), hospitality healthcare hubs in Malaysia, and diagnostic solution partnerships.
The Pellucidcare restructuring aligns with FMV's broader expansion in point-of-care diagnostic solutions and reinforces its strategic positioning in the diagnostic healthcare ecosystem. This internal reorganization optimizes operational efficiency and consolidates diagnostic capabilities within the subsidiary structure, supporting the company's stated vision of leveraging AI, Big Data, and Computing (ABC framework) to enhance healthcare accessibility and affordability.
The transfer reflects FMV's commitment to vertical integration and portfolio optimization within India's growing diagnostic imaging sector, though the specific financial quantum and transaction timelines remain subject to regulatory approvals.
Fischer Medical Ventures informs about reconstitution of committees
Stock NewsFISCHER2 Jan 2026
NULL
Fischer Medical Ventures informs about press release
Stock NewsFISCHER13 Nov 2025
NULL
Fischer Medical Ventures’ arm wins order worth Rs 9.29 crore
Stock NewsFISCHER13 Nov 2025
The order is for supplying and installing 65 advanced Digital Radiography units across Tamil Nadu
Fischer Medical Ventures informs about press release
Stock NewsFISCHER11 Nov 2025
NULL
Fischer Medical Ventures informs about audio recording of conference call
Stock NewsFISCHER7 Nov 2025
NULL

